Pharmaceutical Abstracts
2024 American Society of Cataract and Refractive Surgery
![](/sites/g/files/rbvwei1736/files/styles/535x400/public/2024-03/Screenshot%202024-03-22%20at%2010.03.22%E2%80%AFAM.png?itok=MEhFHBmW)
Pharmaceutical Posters
2023 American Academy of Optometry
![](/sites/g/files/rbvwei1736/files/styles/535x400/public/2024-03/Screenshot%202024-03-22%20at%2010.27.16%E2%80%AFAM.png?itok=nw2V1t71)
RHOPRESSA® (netarsudil ophthalmic solution) 0.02%
RHOPRESSA® s a prescription medicine to reduce high eye pressure (intraocular pressure, or IOP) in patients with open-angle glaucoma or ocular hypertension
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
ROCKLATAN® is a combination of two prescription medicines to reduce high eye pressure (intraocular pressure, or IOP) in patients with open-angle glaucoma or ocular hypertension
SIMBRINZA® (brinzolamide and brimonidine tartrate ophthalmic suspension) 1%/0.2%
SIMBRINZA® is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension